Hyperhomocysteinemia and cardiovascular diseases.
cardiovascular
homocysteine
hyperhomocysteinemia
Journal
Annales de biologie clinique
ISSN: 1950-6112
Titre abrégé: Ann Biol Clin (Paris)
Pays: France
ID NLM: 2984690R
Informations de publication
Date de publication:
01 Feb 2022
01 Feb 2022
Historique:
pubmed:
8
2
2022
medline:
4
3
2022
entrez:
7
2
2022
Statut:
ppublish
Résumé
Homocysteine (Hcy) is a sulfhydryl-containing amino acid, which is not acquired through the diet, but rather synthesized as an intermediate metabolite in the methionine cycle. Hcy is present in plasma, with normal levels between 5 and 15 μmol/L, a slightly elevated level between 15 to 30 μmol/L, moderate from 30 to 100 μmol/L and a value > 100 μmol/L classified as severe hyperhomocysteinemia (HHcy). HHcy has been associated with inflammation and atherosclerosis and is considered an independent risk factor for cardiovascular diseases (CVD). Here, we review the main evidence showing the association and the possible involvement of HHcy in the most common CVD.
Identifiants
pubmed: 35129442
pii: abc.2021.1694
doi: 10.1684/abc.2021.1694
doi:
Substances chimiques
Homocysteine
0LVT1QZ0BA
Methionine
AE28F7PNPL
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM